KRAS and non-small cell lung carcinoma: Skoulidis et al. showed STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant patients, identifying STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1/PD-L1 inhibitors in KRAS-mutant NSCLC [87,174,219]